Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: The immune response to COVID-19 vaccination is inferior in kidney transplant recipients (KTRs) and to a lesser extent in patients on dialysis or with chronic kidney disease (CKD). We assessed the immune response 6 months after mRNA-1273 vaccination in kidney patients and compared this to controls.
METHODS: A total of 152 participants with CKD stages G4/5 (eGFR <30 mL/min/1.73 m2), 145 participants on dialysis, 267 KTRs, and 181 controls were included. SARS-CoV-2 Spike S1 specific IgG antibodies were measured using fluorescent bead-based multiplex-immunoassay, neutralizing antibodies to ancestral, Delta, and Omicron (BA.1) variants by plaque reduction, and T-cell responses by interferon-γ release assay.
RESULTS: At 6 months after vaccination, S1-specific antibodies were detected in 100% of controls, 98.7% of CKD G4/5 patients, 95.1% of dialysis patients, and 56.6% of KTRs. These figures were comparable to the response rates at 28 days, but antibody levels waned significantly. Neutralization of the ancestral and Delta variants was detected in most participants, whereas neutralization of Omicron was mostly absent. S-specific T-cell responses were detected at 6 months in 75.0% of controls, 69.4% of CKD G4/5 patients, 52.6% of dialysis patients, and 12.9% of KTRs. T-cell responses at 6 months were significantly lower than responses at 28 days.
CONCLUSIONS: Although seropositivity rates at 6 months were comparable to rates at 28 days after vaccination, significantly decreased antibody levels and T-cell responses were observed. The combination of low antibody levels, reduced T-cell responses, and absent neutralization of the newly emerging variants indicates the need for additional boosts or alternative vaccination strategies in KTRs.
CLINICAL TRIALS REGISTRATION: NCT04741386.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 76(2023), 3 vom: 08. Feb., Seite e188-e199 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.02.2023 Date Revised 20.02.2023 published: Print ClinicalTrials.gov: NCT04741386 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciac557 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343171260 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343171260 | ||
| 003 | DE-627 | ||
| 005 | 20231226015814.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciac557 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1143.xml |
| 035 | |a (DE-627)NLM343171260 | ||
| 035 | |a (NLM)35796536 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sanders, Jan-Stephan F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2023 | ||
| 500 | |a Date Revised 20.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT04741386 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: The immune response to COVID-19 vaccination is inferior in kidney transplant recipients (KTRs) and to a lesser extent in patients on dialysis or with chronic kidney disease (CKD). We assessed the immune response 6 months after mRNA-1273 vaccination in kidney patients and compared this to controls | ||
| 520 | |a METHODS: A total of 152 participants with CKD stages G4/5 (eGFR <30 mL/min/1.73 m2), 145 participants on dialysis, 267 KTRs, and 181 controls were included. SARS-CoV-2 Spike S1 specific IgG antibodies were measured using fluorescent bead-based multiplex-immunoassay, neutralizing antibodies to ancestral, Delta, and Omicron (BA.1) variants by plaque reduction, and T-cell responses by interferon-γ release assay | ||
| 520 | |a RESULTS: At 6 months after vaccination, S1-specific antibodies were detected in 100% of controls, 98.7% of CKD G4/5 patients, 95.1% of dialysis patients, and 56.6% of KTRs. These figures were comparable to the response rates at 28 days, but antibody levels waned significantly. Neutralization of the ancestral and Delta variants was detected in most participants, whereas neutralization of Omicron was mostly absent. S-specific T-cell responses were detected at 6 months in 75.0% of controls, 69.4% of CKD G4/5 patients, 52.6% of dialysis patients, and 12.9% of KTRs. T-cell responses at 6 months were significantly lower than responses at 28 days | ||
| 520 | |a CONCLUSIONS: Although seropositivity rates at 6 months were comparable to rates at 28 days after vaccination, significantly decreased antibody levels and T-cell responses were observed. The combination of low antibody levels, reduced T-cell responses, and absent neutralization of the newly emerging variants indicates the need for additional boosts or alternative vaccination strategies in KTRs | ||
| 520 | |a CLINICAL TRIALS REGISTRATION: NCT04741386 | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a dialysis | |
| 650 | 4 | |a kidney transplantation | |
| 650 | 4 | |a mRNA-1273 vaccine | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Messchendorp, A Lianne |e verfasserin |4 aut | |
| 700 | 1 | |a de Vries, Rory D |e verfasserin |4 aut | |
| 700 | 1 | |a Baan, Carla C |e verfasserin |4 aut | |
| 700 | 1 | |a van Baarle, Debbie |e verfasserin |4 aut | |
| 700 | 1 | |a van Binnendijk, Rob |e verfasserin |4 aut | |
| 700 | 1 | |a Diavatopoulos, Dimitri A |e verfasserin |4 aut | |
| 700 | 1 | |a Geers, Daryl |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitz, Katharina S |e verfasserin |4 aut | |
| 700 | 1 | |a GeurtsvanKessel, Corine H |e verfasserin |4 aut | |
| 700 | 1 | |a den Hartog, Gerco |e verfasserin |4 aut | |
| 700 | 1 | |a Kho, Marcia M L |e verfasserin |4 aut | |
| 700 | 1 | |a Koopmans, Marion P G |e verfasserin |4 aut | |
| 700 | 1 | |a van der Molen, Renate G |e verfasserin |4 aut | |
| 700 | 1 | |a Remmerswaal, Ester B M |e verfasserin |4 aut | |
| 700 | 1 | |a Rots, Nynke |e verfasserin |4 aut | |
| 700 | 1 | |a Gansevoort, Ron T |e verfasserin |4 aut | |
| 700 | 1 | |a Bemelman, Frederike J |e verfasserin |4 aut | |
| 700 | 1 | |a Hilbrands, Luuk B |e verfasserin |4 aut | |
| 700 | 1 | |a Reinders, Marlies E J |e verfasserin |4 aut | |
| 700 | 0 | |a VACcination Immune Response Study (RECOVAC) Collaborators |e verfasserin |4 aut | |
| 700 | 1 | |a Abrahams, Alferso C |e investigator |4 oth | |
| 700 | 1 | |a Baas, Marije C |e investigator |4 oth | |
| 700 | 1 | |a Bouwmans, Pim |e investigator |4 oth | |
| 700 | 1 | |a Ten Dam, Marc A G J |e investigator |4 oth | |
| 700 | 1 | |a Gommers, Lennert |e investigator |4 oth | |
| 700 | 1 | |a Frölke, Sophie C |e investigator |4 oth | |
| 700 | 1 | |a Standaar, Dorien |e investigator |4 oth | |
| 700 | 1 | |a van der Heiden, Marieke |e investigator |4 oth | |
| 700 | 1 | |a Imhof, Celine |e investigator |4 oth | |
| 700 | 1 | |a Adema, Yvonne M R |e investigator |4 oth | |
| 700 | 1 | |a Malahe, Reshwan K |e investigator |4 oth | |
| 700 | 1 | |a Boer-Verschragen, Marieken J |e investigator |4 oth | |
| 700 | 1 | |a Mattheussens, Wouter B |e investigator |4 oth | |
| 700 | 1 | |a Philipsen, Ria |e investigator |4 oth | |
| 700 | 1 | |a van Mourik, Djenolan |e investigator |4 oth | |
| 700 | 1 | |a Bogers, Susanne |e investigator |4 oth | |
| 700 | 1 | |a van Dijk, Laura L A |e investigator |4 oth | |
| 700 | 1 | |a Hemmelder, Marc H |e investigator |4 oth | |
| 700 | 1 | |a de Vries, Aiko P J |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 76(2023), 3 vom: 08. Feb., Seite e188-e199 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2023 |g number:3 |g day:08 |g month:02 |g pages:e188-e199 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciac557 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2023 |e 3 |b 08 |c 02 |h e188-e199 | ||